Business
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
— Technology currently being evaluated for the treatment of ovarian cancer in Phase 1 clinical trial — SAN JOSE, Calif., July 11, 2023 /PRNewswire/ -- Anixa
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"— Technology currently being evaluated for the treatment of ovarian cancer in Phase 1 clinical trial —\nSAN JOSE, Calif., July 11, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center. \n\n \n \n \n \n \n \n\n \nThe patent, entitled \"Methods and Compositions for Treating Cancer,\" covers a nucleic acid that encodes a chimeric protein whose domains can be used to treat certain types of cancer by binding to specific hormone receptors and activating T cells. The patent was invented by Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt, both formerly of The Wistar Institute, to which the patent is assigned, along with Anixa's majority-owned subsidiary, Certainty Therapeutics, Inc., which is the exclusive, world-wide licensee.\nDr. Amit Kumar, Chairman and CEO of Anixa, stated, \"We are pleased that our CAR-T technology has received additional intellectual property protection in a market outside the U.S. Our novel CAR-T technology takes advantage of specific hormone-to-hormone receptor biology to address malignancies and has the potential to be the first successful CAR-T therapy against solid tumors. While our initial focus is on the treatment of ovarian cancer — with a Phase 1 clinical trial currently ongoing — the technology covered by the patent has broad application and could potentially also be used to treat other solid tumors by exploiting an anti-angiogenesis mechanism of action.\"\nAbout Anixa's CER-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology)\nAnixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric ...